Sun Pharma and Philogen sign licence agreement for anti-cancer therapy

30 May 2023
www.pharmaceutical-technology.com
License out/inPhase 3Immunotherapy
Sun Pharma and Philogen sign licence agreement for anti-cancer therapy
Preview
Source: Pharmaceutical Technology
Malignant melanoma on the right upper medial back, marked for biopsy. Credit: Dermanonymous / commons.wikimedia.org.
Sun Pharmaceutical Industries has reached a licence agreement with Philogen for the commercialisation of Philogen’s Nidlegy (Daromun) in Australia, New Zealand and Europe.
Nidlegy is a new anti-cancer biopharmaceutical being developed to treat patients with melanoma and non-melanoma skin cancers. It is currently undergoing Phase III clinical studies.
Recommended Reports
Sun Pharma and Philogen sign licence agreement for anti-cancer therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Omiganan Pentahydrochloride in Vulvar Cancer GlobalData
Sun Pharma and Philogen sign licence agreement for anti-cancer therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Tivozanib Hydrochloride in Pancreatic Cancer GlobalData
View all
Nidlegy is composed of L19TNF and L19IL2, two active ingredients which are produced separately and then combined before being administered via the intralesional method.
Philogen CEO and CSO Professor Dr Dario Neri stated: “This collaboration will focus on the commercialisation of Nidlegy, a new immunotherapy that brings promise to improve the therapeutic options for patients suffering from melanoma and non-melanoma skin cancers, high-risk conditions with unmet medical need.”
Sun Pharma has been granted exclusive commercialisation rights for Nidlegy in the three countries for the treatment of skin cancers.
Philogen will hold intellectual property rights for Nidlegy in other territories and indications, excluding skin cancers.
It intends to conclude pivotal clinical studies for Nidlegy in Europe and to seek marketing authorisation from the regulatory authorities.
The company will also be involved in the manufacture of commercial supplies.
Sun Pharma will take responsibility for the commercialisation of the product.
Post-commercialisation costs will be split equally between the two companies.
Sun Pharma Western Europe and ANZ business head Hellen De Kloet stated: “This collaboration is in line with our goal to bring innovative products to patients.
“With the expected addition of Nidlegy to our existing Odomzo franchise, we will be well-positioned to provide patient solutions across a broad spectrum of skin cancers in various disease stages.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.